auro-carvedilol 3.125
aurobindo pharma nz limited - carvedilol 3.125mg - film coated tablet - 3.125 mg - active: carvedilol 3.125mg excipient: colloidal silicon dioxide crospovidone hypromellose lactose monohydrate macrogol 400 magnesium stearate polysorbate 80 povidone purified water sucrose titanium dioxide - indicated for the management of essential hypertension. it can be used alone or in combination with other antihypertensive agents (e.g. calcium channel blockers, diuretics).
dp-carvedilol
douglas pharmaceuticals limited - carvedilol 3.125mg; - film coated tablet - 3.125 mg - active: carvedilol 3.125mg excipient: colloidal silicon dioxide crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-22-18096 povidone - hypertension dp-carvedilol is indicated for the management of essential hypertension. it can be used alone or in combination with other antihypertensive agents (eg calcium channel blockers, diuretics).
apo-carvedilol
apotex nz ltd - carvedilol 3.125mg - tablet - 3.125 mg - active: carvedilol 3.125mg excipient: croscarmellose sodium hyetellose lactose monohydrate macrogol 8000 magnesium stearate microcrystalline cellulose titanium dioxide - apo-carvedilol is indicated for the management of essential hypertension. it can be used alone or in combination with other antihypertensive agents (e.g. calcium channel blockers, diuretics).
carvedilol 3.125mg tablets
bristol laboratories ltd - carvedilol - oral tablet - 3.125mg
apo-carvedilol carvedilol 3.125 mg tablet blister pack
arrotex pharmaceuticals pty ltd - carvedilol, quantity: 3.125 mg - tablet, film coated - excipient ingredients: crospovidone; microcrystalline cellulose; colloidal anhydrous silica; povidone; magnesium stearate; lactose monohydrate; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).
apo-carvedilol carvedilol 25 mg tablet blister pack
arrotex pharmaceuticals pty ltd - carvedilol, quantity: 25 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; lactose monohydrate; microcrystalline cellulose; crospovidone; colloidal anhydrous silica; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).
apo-carvedilol carvedilol 12.5 mg tablet blister pack
arrotex pharmaceuticals pty ltd - carvedilol, quantity: 12.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; magnesium stearate; crospovidone; microcrystalline cellulose; povidone; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).
apo-carvedilol carvedilol 6.25 mg tablet blister pack
arrotex pharmaceuticals pty ltd - carvedilol, quantity: 6.25 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; magnesium stearate; povidone; lactose monohydrate; colloidal anhydrous silica; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).
carvedilol- carvedilol tablet
cipla usa inc. - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 3.125 mg - carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ace inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see drug interactions (7.4), clinical studies (14.1)] . carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see clinical studies (14.2)] . carvedilol tablets are indicated for the management of essential hypertension [see clinical studies (14.3, 14.4)] . it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see drug interactions (7.2)] . carvedilol is contraindicated in the following conditions: - bronchial asthma or related bronchospastic conditions. deaths from status
carvedilol 3.125mg film-coated tablets
aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - carvedilol - film-coated tablet - carvedilol 3.125 mg - beta blocking agents